Table 1 The association of MIP-1α/CCL3 with periodontitis as measured in bodily fluids. G gingivitis, CP chronic periodontitis, AP aggressive periodontitis, H healthy periodontal tissue group, GCF gingival crevicular fluid, LAgP localized aggressive periodontitis, OHI oral hygiene instructions, SRP scaling, and root planing
From: Macrophage Inflammatory Protein-1 Alpha (MIP-1 alpha)/CCL3: As a Biomarker
Sample | Periodontal disease | Main finding | References | |||
|---|---|---|---|---|---|---|
G | CP | AP | H | |||
Serum | 17 | 8 | MIP-1α/CCL3 level was found to be elevated in the test group | de Queiroz et al. 2008 | ||
GCF | 15 | 26 | 26 | 15 | No significant difference in levels of MIP-1α/CCL3 was found between patients with gingivitis, patients with periodontitis (chronic or aggressive), and the healthy control group | Emingil et al. 2005 |
GCF | 40 (20 smokers 20 nonsmokers) | 12 | MIP-1α/CCL3 levels were lower in patients with periodontitis who smoked than in those who did not smoke | Tymkiw et al. 2011 | ||
Saliva | 7 Aa+ group who developed bone loss | 7 Aa+, healthy group subjects with no bone loss | MIP-1α/CCL3 levels were 50-fold higher in subjects with LAgP Aa+ group | Fine et al. 2009 | ||
7 Aa−, healthy group | The levels of MIP-1α/CCL3 were found to be increased 6–9 months before the detection of bone loss | |||||
Saliva | 40 | 40 | MIP-1α/CCL3 levels were 18-fold higher in the periodontitis group | Al-Sabbagh et al. 2012 | ||
Saliva | 33 (OHI) 35 (SRP+ OHI) | A significant reduction in MIP-1α/CCL3 levels was found in patients who responded to periodontal therapy (SRP + OHI) compared to those who did not | Sexton et al. 2011 | |||